NVST - NYSE
Envista Holdings Corp
$22.40
-0.47%Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
At a Glance
Live Snapshotnvst
Total Liabilities
Last Annual Value
2.57B
3-Year CAGR
3%
5-Year CAGR
-4%
10-Year CAGR
10%
Envista Holdings Corp Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Envista Holdings Corp NYSE:NVST | 2.57B | 1.9% | 0.4% | N/A | |
 GRAIL, Inc. NASDAQ:GRAL | 344.15M | -27.7% | 2.3% | N/A | |
 DENTSPLY SIRONA Inc. NASDAQ:XRAY | 4.09B | 0.1% | -0.7% | 1.5% | |
 Privia Health Group, Inc. NASDAQ:PRVA | 578.43M | 13.8% | 19.6% | N/A | |
2.62B | 25.9% | N/A | N/A | ||
 Supernus Pharmaceuticals, Inc. NASDAQ:SUPN | 390.93M | 3.2% | -14.8% | 12.7% | |
 ICU Medical, Inc. NASDAQ:ICUI | 1.93B | -5.1% | 48.7% | 45.8% | |
 Alignment Healthcare, Inc. NASDAQ:ALHC | 886.51M | 26.9% | 22.2% | N/A | |
 Apogee Therapeutics, Inc. NASDAQ:APGE | 33.25M | 15.7% | N/A | N/A | |
 Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | 1.60B | 9.7% | 21.8% | 37.5% | |
 Dyne Therapeutics, Inc. NASDAQ:DYN | 214.83M | 42.8% | 30.2% | -32.5% |
Envista Holdings Corp Fair Value Envelope
Related Guides
Continue your NVST research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.